More personalised cancer treatments in the pipeline as MVision AI gains $5.8M in funding

Finnish medical imaging and AI startup MVisionAI, has announced it has secured $5.8M in post-seed financing. 

The company's AI-powered automated-segmentation tool allows for more personalised treatment planning, minimising the radiation dose to healthy organs. The model uses CT or MRI scans, producing 3D volumes of organs and tumours, reducing radio oncologist work burden and time to diagnosis by automating manual tasks. The platform has received a CE-mark and FDA-clearance for the auto-segmentation feature for radiotherapy planning. 

The new investment will be used for research and development of new solutions to speed up radiotherapy treatment planning and to build a globally scalable cloud-based platform for cancer treatment. 

“We’re also looking to further expand and bring the solution [to] more patients globally. Our mission is to build a globally scalable cloud platform for a clinical decision support system for cancer care.” said MVision’s founder and CEO, Mahmudul Hasan.